|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Azactam
We licensed the U.S. marketing rights to this injectable
antibiotic from Bristol-Myers Squibb Company (Bristol-Myers) in
January 1999. Azactam is a monobactam and is principally
used by surgeons, infectious disease specialists and internal
medicine physicians to treat pneumonia, post-surgical infections
and septicemia. Azactam is often used in these infections
for patients who have a known or suspected penicillin allergy.
For 2008, revenue from Azactam increased 12% to
$96.9 million, compared to $86.3 million for 2007. The
increase for the period reflects a combination of increased
demand and price. Azactam lost its patent exclusivity in
Table of Contents
October 2005 and its future sales are expected to be negatively
impacted by generic competition. However, no generic form of
Azactam has been approved to date.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Azactam
We licensed the U.S. marketing rights to this injectable
antibiotic from Bristol-Myers in January 1999. Azactam is
a monobactam and is principally used by surgeons, infectious
disease specialists and internal medicine physicians to treat
pneumonia, post-surgical infections and septicemia. Azactam
is often used in these infections for patients who have a
known or suspected penicillin allergy. Revenue from sales of
Azactam totaled $86.3 million for 2007 (2006:
$77.9 million). The basic U.S. patent on Azactam
expired in October 2005. No generic Azactam product
has been approved to date. While Azactam is available
through distributors, we no longer promote this product.
Please refer to Item 5.A. “Operating Results” for
additional information concerning our revenue by category for
2007, 2006 and 2005.
Table of Contents
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Azactam
We licensed the US marketing rights to this injectable
antibiotic from Bristol-Myers in January 1999. Azactam is
a monobactam and is principally used by surgeons, infectious
disease specialists and internal medicine physicians to treat
pneumonia, post-surgical infections and septicemia. Azactam
is often used in these infections for patients who have a
known or suspected penicillin allergy. Revenue from sales of
Azactam totaled $77.9 million for 2006 (2005:
$57.7 million). The basic US patent on Azactam
expired in October 2005. No generic Azactam product
has been approved to date, however we expect that generic
competition to Azactam will emerge in 2007.
Please refer to Item 5A. “Operating Results” for
additional information concerning our revenue by category for
2006, 2005 and 2004.
Table of Contents
Table of Contents
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Azactam
We licensed the U.S. marketing rights to this injectable
antibiotic from Bristol-Myers in January 1999. Azactam is
a monobactam and is principally used by surgeons, infectious
disease specialists and internal medicine physicians to treat
pneumonia, post-surgical infections and septicemia. Revenue from
sales of Azactam totalled $57.7 million for 2005.
The basic U.S. patent on Azactam expired in October
2005. To date, no generic Azactam product has been
approved. However, we expect that generic competition to
Azactam will emerge in 2006.
Please refer to Item 5.A “Operating Results” for
additional information concerning our revenue by category for
2005, 2004 and 2003.
Table of Contents
Table of Contents
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
